

Pleiotropic Genetic Effects between Multiple Sclerosis and Musculoskeletal

Traits

Sohyun Jeong^{1,2}, Ming-Ju Tsai^{1,2}, Changbing Shen^{3,4}, Yi-Hsiang Hsu^{1,2,5}

¹Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Boston 02131, MA

²Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School,

³Boston 02215, MA Department of Dermatology, Peking University Shenzhen Hospital, Shenzhen 518036, Guangdong, China

⁴Shenzhen Key Laboratory for Translational Medicine of Dermatology, Shenzhen Peking University - The Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, Guangdong, China

⁵Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA

Corresponding author: Yi-Hsiang Hsu, M.D., Sc. D.

Email: yihsianghsu@hsl.harvard.edu

Tel and Fax: 1-617-971-5368

Abstract

Background Musculoskeletal disorders were commonly reported in patients with multiple sclerosis. However, the underlying etiology linking Multiple Sclerosis (MS) and musculoskeletal disorders is not well studied. With large-scale Genome-Wide Association Studies (GWAS) publicly available, we conducted genetic correlation analysis to identify shared pleiotropic genetic effects between MS and musculoskeletal traits. We also conducted Mendelian Randomization (MR) to estimate the causal relation between MS and increased risks of musculoskeletal disorders.

Methods Linkage Disequilibrium Score Regression (LDSR) analysis was performed to estimate heritability and genetic correlation. Univariable, multivariable, and bidirectional MR analyses were conducted to estimate the causal relation. These analyses were done by utilizing the recent GWAS summary statistics of MS, fracture, frailty, falls, and several musculoskeletal risk factors, including bone mineral density, lean mass, grip strengths, and vitamin D.

Results LDSR analysis showed a moderate genetic correlation of MS with falls ($R_G=0.10$, $p=0.01$) but not with fracture and frailty. Genetic variants (rs13191659) in *LINC00240* gene which is associated with iron status biomarkers was found to be associated with both MS and falls. In MR analyses after excluding outlier SNPs with potential pleiotropic effects and correcting for multiple testing, MS presented no causal association with fracture and frailty but a minimal association with falls. Falls showed causally increased risks of fracture and frailty.

Conclusion Our study suggests a potential genetic correlation with shared pleiotropic genetic

effects between MS and falls. However, we didn't find evidence to support the causal relation between MS and increased risks of falls, fracture, and frailty.

Keywords: LD score regression, Multivariable Mendelian Randomization, Bidirectional Mendelian Randomization, Fracture, Falls, Frailty

Introduction

Multiple sclerosis (MS) is a demyelinating inflammatory autoimmune disorder presenting continuous and diffuse changes in the white and grey matter, breakdown of myelin, and damage to axons [1]. Despite recent progress characterized by the advent of new disease-modifying therapies, patients with MS still show an increased risk of musculoskeletal disorders such as fracture [2, 3], accidents and falls [4], and frailty [5] compared to controls. A meta-analysis comprising 9 cohort studies proposed significantly increased fracture risk in MS by 1.58 times compared to controls [6]. Falls are a debilitating consequence of MS and 56% of MS patients experience falls in any 3-month period [4]. Frailty is a marker of poor prognosis in patients suffering from systemic sclerosis [5] and a significantly higher percentage of MS patients were frail compared to controls (28% vs 8%) [5].

Multiple attributable risk factors of musculoskeletal disorders of MS have been proposed, including secondary causes delineating systemic bone loss by chronic inflammatory status [7], muscle weakness due to immobility [8], and ataxia from disruption of neuronal impulses [9], as well as bone and muscle loss due to MS treatment such as corticosteroids use [10], and psychotropic drugs (antidepressants, anxiolytics, and anti-epileptics) use [11, 12], which make MS patients vulnerable to falls. Beyond the secondary causes, intrinsic factors of MS etiology might be associated with the increased musculoskeletal disorders such that early stage comparatively young MS patients with minimal or no physical disability also presented

low BMD [13].

However, most of the findings were typical observational studies not precluding potential biases from undefined residual confounding and reverse causation. Therefore, the elucidation of the effects of genetically unmodifiable predisposing factors will give further insights into preventative strategies for MS patients' care.

In this context, LDSR is a reliable and efficient method of using GWAS summary-level data to estimate the genetic correlation between different phenotypes [14]. In addition, MR is a widely used method using measured variation in genes (genotypes, SNPs) of exposure to examine the causal effect of exposures on disease outcomes in observational studies [15, 16].

We implemented LD score regression as well as univariable, multivariable and bidirectional MR, and estimated genetic pleiotropic effect (correlation) and direct MS effects to 3 musculoskeletal outcomes (fracture, falls, and frailty) adjusting for the confounding effects from well-established bone and muscle disorder-related risk factors such as bone mineral density (BMD), lean body mass (whole body fat-free mass, appendicular lean mass), grip strengths and vitamin D.

We performed the following analyses: (1) LDSR to assess genetic heritability and genetic pleiotropy (correlations) between MS and musculoskeletal traits; (2) univariable MR to assess the causal effect of genetic determinants of MS on fracture, falls, frailty, and multiple risk factors; (3) multivariable MR to evaluate independent specific effects of MS to fracture, falls, frailty adjusting for other contributing risk factors; (4) bidirectional MR to assess the directionality among fracture, falls, frailty.

Methods

Linkage Disequilibrium Score Regression (LDSR)

We used the LD Hub interface which provides an automatic LD score regression analysis pipeline for users [17]. To standardize the input file, quality control is automatically performed on the uploaded file in LD Hub. In order to restrict the analysis to well-imputed SNPs, LD Hub filters the uploaded SNPs to HapMap3 SNPs [18] with 1000 Genomes EUR MAF above 5%, which tend to be well-imputed in most studies. In addition, to make the estimates of the genetic correlation to be reliable, the recent MS GWAS meta-analysis of the International Multiple Sclerosis Genetics Consortium (IMSGC) comprising 47,429 cases and 68,374 controls [19] needs to meet the following criteria; 1) Z score is at least > 1.5 (optimal > 4), 2) Mean Chi-square of the test statistics > 1.02 , and 3) the intercept estimated from the SNP heritability analysis is between 0.9 and 1.1 [17]. We used UK Biobank GWAS datasets provided by LD hub pipeline estimating genetic heritability and correlation with MS.

Mendelian Randomization (MR)

Supplementary Table 1 describes the detailed data source used in MR study. The largest publicly available GWAS summary statistics were used. Most GWAS summary statistics data were downloaded from the “MRC IEU OpenGWAS database” repository (<https://gwas.mrcieu.ac.uk/>) or each GWAS consortia. The overall study design for MR is displayed in Fig 1.

Exposure data: Instrumental variables (IVs) for MS are obtained from the recent GWAS meta-analysis of the IMSGC [19]. Among the 233 genome-wide statistically independent associations with MS susceptibility, 200 effects (SNPs) located in the autosomal non-MHC genome were selected as IVs (Supplementary Table 2). The detailed analysis and results description is provided in the previous IMSGC publication [19]. SNPs of genome-wide and suggestive effects jointly explain ~48% of the estimated heritability for MS [19].

Outcome data: Fracture and falls GWAS data used in the analysis were selected from the UK Biobank data, fractured/broken in last 5 years (ID: ukb-b-13346, n=44,502 cases and 415,887 controls) [20] and falls last year (ID: ukb-b-2535, n=461,725). Frailty GWAS data was from Atkins et al, 2019 (n=175,226) [21].

Risk factors of musculoskeletal outcomes: Known bone and muscle strength-related factors were used as covariates in MVMR. They are eBMD (heel)[22], appendicular lean mass, whole body fat-free mass, right handgrip strength, left grip strength [23] vitamin D [24], frailty [21], and falls [25].

Statistical analysis

Univariable MR between MS and three musculoskeletal traits as well as risk factors

Univariable MR was applied to assess the causal relation between MS and 3 musculoskeletal outcomes (fracture, falls, and frailty) and 5 risk factors. Furthermore, MR effects of musculoskeletal risk factors on 3 musculoskeletal outcomes were assessed to examine the potential genetically determined risk paths of 3 musculoskeletal outcomes. Multi-instrument MR approaches were applied, which were to perform a single instrumental variable MR first; and then combined MR results from multiple instrumental variables via fixed-effect meta-analysis to estimate the overall causal relationships.

MVMR between MS and three musculoskeletal outcomes adjusting for risk factors

We also applied regression-based MVMR to account for many variants having pleiotropic effects that are associated with multiple risk factors in order to provide coefficients (effect sizes) representing the direct causal effects of MS to three musculoskeletal outcomes in turn with the other risk factors being fixed. MVMR is an extension of MR to deal with genetic variants that are associated with multiple risk factors. We selected risk factors that are known

to be biologically related to musculoskeletal traits and where there is a potential network of causal effects (mediation) from one risk factor to another. The causal estimate is obtained by regression of the associations with the outcome on the associations with the risk factors, with the intercept set to zero and weights being the inverse-variances of the associations with the outcome [26]. Risk factors presenting significant univariable MR association with each musculoskeletal trait were included in MVMR.

Bidirectional MR among the three musculoskeletal outcomes

Bidirectional MR was performed among fracture, fall and frailty to examine their mutual effects and directionality considering their highly correlative nature. In bidirectional MR, instruments for both exposure and outcome are used to evaluate whether the “exposure” variable causes the “outcome” or whether the “outcome” variable causes the “exposure”[27].

Heterogeneity analysis

We used Cochran’s Q statistic to check the heterogeneity of IVs. Heterogeneity indicates a possible violation of the necessary IVs or modeling assumptions of which pleiotropy is a likely major cause. Cochran’s Q statistic derived from the inverse variance weighted (IVW) estimate should follow a χ^2 distribution with degrees of freedom equal to the number of SNPs minus 1. Excessive heterogeneity is an indication that either the modeling assumptions have been violated, or that some of the genetic variants violate the IV assumptions—e.g. by exerting a direct effect on the outcome, not through the exposure [28]. This is termed ‘horizontal pleiotropy’[29].

When Q statistics showed significant heterogeneity, we applied MR-PRESSO [30] method to reassess the MR effects after filtering out outlier SNPs and compared the fixed MR results with IVW-based results.

Sensitivity analysis

The sensitivity analysis including IVW, weighted median, weighted mode, and MR-Egger tests were performed in univariable MR analysis. For MVMR, IVW and MR-Egger tests were evaluated. To exclude instrumental variables that may have horizontal pleiotropy and cause false positive findings of the causal inference, we also applied the MR-Egger regression test [31] to verify horizontal pleiotropy in each MR. Among the multiple methods, we set the results from IVW and MR-PRESSO outlier removal results as primary findings.

All the MR analyses were conducted in R (version 4.0.0) using TwoSampleMR [32], MendelianRandomization [33], MRPRESSO [34] packages, and the MR-Base platform [35]. The causal effect size (beta) with standard error and p-values were presented as appropriately. We applied a false discovery rate (FDR) to correct for multiple testing. The criteria used to select final instrument variables in each MR were GWAS significance: $p < 5e^{-8}$, LD clumping: $r^2 > 0.001$ within a 10MB window, and proxy SNPs in 1000 Genomes EUR $r^2 = 0.8$ [36].

Results

Genetic heritability and correlations by LDSR

Regression weight LD Scores for 1,293,150 SNPs of MS GWAS data were read. After merging with reference panel LD, a total of 1,109,876 SNPs remained for the final analysis. LDSR demonstrated that MS has statistically significant moderate genetic correlation with falls (rG: 0.105, $p = 0.010$) but not with fracture (rG: -0.017, $p = 0.711$) or frailty (rG: 0.151, $p = 0.082$). Both handgrip strengths and both leg fat-free masses also showed a genetically significant correlation with MS. However, the whole-body fat free mass didn't have a significant correlation with MS. The heritability of these traits estimated from GWAS summary statistics was low or considered not high; fracture ($h^2: 0.019$), falls ($h^2: 0.033$), and

frailty (h^2 : 0.015) (Table 1). We found genetic variant rs13191659 mapped to *LINC00240* (Long Intergenic Non-Protein Coding RNA 240) gene is commonly associated with MS and fall (MS GWAS $p < 5e-8$ and fall GWAS $< 5e-5$). *LINC00240* is known for total iron binding capacity [37], folic acid deficiency anemia and mean corpuscular volume [38].

Mendelian Randomization

The univariable MR analysis showed a minimal causal effect of the total 109 MS SNPs to fracture, falls, and frailty in the IVW method. After excluding SNP outliers by MR-PRESSO and applying multiple testing corrections, without meaningful ORs, MS doesn't seem to causally increase risks of falls (OR:1.004, 95% CI: 1.001-1.006, $q=0.018$); fracture (OR:1.002, 95% CI:1.000-1.003, $q=0.056$) and frailty score (beta:0.009, 95% CI: 0.001-0.017, $q=0.147$) and none of the univariable MR effects between MS and musculoskeletal risk factors were significant (Table 2 & Supplementary Table 3). Sensitivity analyses with different MR methods such as MR Egger, Weighted median, and Weighted mode methods didn't replicate the significant results in all the MR analyses. All pleiotropy tests (MR Egger intercept test) were insignificant (Supplementary Table 3). Single SNP MR effects between MS and falls are presented in Supplementary Table 4 & 5. In MVMR analysis, except for adjustment of frailty, adjustment of each risk factor didn't modify the overall MR results between MS and fall (Table 3). MVMR between MS and fracture as well as MS and frailty presented similar results that adjustment for each risk factor had no meaningful modification in overall MR results (Supplementary Table 6 & 7).

To account for the directional effects among the 3 musculoskeletal outcomes; fracture, fall and frailty, we conducted bidirectional MR. As expected, Fall causally increased fracture risk (OR:1.215, 95% CI: 1.098-1.345, $p=1.63E-04$) and frailty risk (OR: 4.870, 95% CI: 2.412-

9.832, $p=1.01E-05$).

Discussion

In this study, we found genetic correlation with shared pleiotropic effects between MS and fall proven by LDSR and MR with minimal effect size. However, we don't find meaningful causal relation to support epidemiological observation with increased musculoskeletal traits in MS patients. The MS doesn't causally increase risks of musculoskeletal traits. Based on the univariable MR between MS and musculoskeletal risk factors, none of the well-known muscle and bone-related risk factors (whole-body and appendicular fat-free masses, both grip strengths, heel BMD and vitamin D) were causally affected by MS. In bidirectional MR among the three musculoskeletal outcomes, fall causally increased fracture and frailty risk.

Taking into all these findings together, we didn't provide evidence to support that MS causally increased risks of neither musculoskeletal traits nor other musculoskeletal risk factors. The widely observed musculoskeletal disorders in MS patients in clinical studies might be more likely due to secondary factors that are associated with MS disease progression and treatment.

When we further explored SNPs commonly found in MS and fall with the criteria of GWAS/suggestive GWA significant variants, genetic variants mapped to a gene associated with iron biomarkers was found. Therefore, we could hypothesize MS and falls share pleiotropic genetic effects in iron biomarker pathways. It is well known that there is a correlation between anemia and falls, and specifically patients with lower hemoglobin levels are more likely to fall [39]. MRI and histological studies also suggest that iron levels are dysregulated in MS: iron accumulates in grey matter and is depleted in normal-appearing white matter [40].

Most of the previous observational studies predominantly reported high fracture risk in MS in comparison to age-matched controls. Dyn one study, Bazelier et al, 2011 [41] reported 3 fold increased hip fracture risk in patients with MS during 5 years of follow-up. However, their baseline fractures were higher in MS than age, sex-matched controls, furthermore the baseline falls history was higher in MS. Therefore, increased fractures observed in MS patients in this study might have been via increased fall risk in this population.

Falls are common in people with MS, with a large international data set demonstrating that 56% MS individuals fall at least once within 3 months period with 37% categorized as frequent fallers [4]. Notably, MS patients fall more frequently and experience more injurious falls, and are more likely to attribute their falls to tripping and distraction [42].

Medication use is a well-established risk factor for falls, either directly (affecting balance, attention, or muscle tone) or indirectly (as proxies of underlying conditions influencing the risk of falling; joint pain, arthrosis, and cardiovascular diseases among many others). A recent falls GWAS study examined the genetic correlation of falls with medication use and found medications such as opioids, anti-inflammatory and anti-rheumatic drugs, anilides, and drugs for peptic ulcer and gastro-esophageal reflux disease were in positive genetic correlations with falls [43]. Medication use associated with MS treatments and complications should be one of the strong risk factors for falls in this population. However, we are not able to evaluate such hypothesis based on our current study design.

Based on our study, genetic factors of MS might predispose MS patients to increased risk of falls by shared genetic pleiotropy but with minimal effects. Therefore, taking into account the secondary environmental or treatment-related factors such as careful medication use and incorporating stringent fall prevention strategy in patient care will mitigate the undesirable

muscle and bone effects in MS patients.

We have a few novelties and strengths to mention. Given the highly increased availability of public GWAS data and identification of thousands of trait-associated loci in each trait, we could utilize LDSR and a multifaceted MR approach together and could elucidate the stepwise causal relations, and draw new perspectives on musculoskeletal traits in MS patients.

We also illuminated genetically predisposed iron biomarker alteration might have a role in fall risk in MS patients. However, we have some limitations. Due to the low heritability of musculoskeletal traits and risk factors (Table 1), incorporating MR analysis might induce limited implications as well as GWAS data from these phenotypes might not highly reliable to elucidate any causal inference.

In conclusion, genetic association between MS and falls still stands, suggesting there are shared pleiotropic genetic factors between these two phenotypes. However, we didn't establish a causal relationship between MS and multiple musculoskeletal traits which were reported by observational studies.

Author contribution

Sohyun Jeong: Conceptualization, Data acquisition, Analysis, Draft and revision of manuscript

Ming-Ju Tsai: Data acquisition, Revision of manuscript

Changbing-Shen: Revision of manuscript

Yi-Hsiang Hsu: Conceptualization, Revision of manuscript

Conflicts of Interest Statement

Sohyun Jeong, Ming-Ju Tsai, Changbing Shen, and Yi-Hsiang Hsu declare that they have no conflict of interest.

Acknowledgement

The author(s) received no financial support for the research, authorship, and/or publication of this article. R01 grant number in the acknowledge section "R01AR72199".

References

1. Lassmann H (2019) Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis. *Front Immunol* 10:
2. Hearn A, Silber E (2010) Osteoporosis in multiple sclerosis. *Mult Scler* 16:1031-1043
3. Marrie R, Cutter G, Tyry T, Vollmer T (2009) A cross-sectional study of bone health in multiple sclerosis. *Neurology* 73:1394-1398
4. Nilsagård Y, Gunn H, Freeman J, Hoang P, Lord S, Mazumder R, Cameron M (2015) Falls in people with MS--an individual data meta-analysis from studies from Australia, Sweden, United Kingdom and the United States. *Mult Scler* 21:92-100
5. Ayrygnac X, Larochelle C, Keezer M, Roger E, Poirier J, Lahav B, Girard M, Prat A, Duquette P (2021) Frailty in ageing persons with multiple sclerosis. *Mult Scler* 27:613-620
6. Dong G, Zhang N, Wu Z, Liu Y, Wang L (2015) Multiple Sclerosis Increases Fracture Risk: A Meta-Analysis. *BioMed Research International* 2015:650138
7. Schett G, David J (2010) The multiple faces of autoimmune-mediated bone loss. *Nat Rev Endocrinol* 6:698-706
8. Formica C, Cosman F, Nieves J, Herbert J, Lindsay R (1997) Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid Use. *Calcif Tissue Int* 61:129-133
9. Josyula S, Mehta B, Karmon Y, Teter B, Batista S, Ostroff J, Weinstock-Guttman B (2012) The nervous system's potential role in multiple sclerosis associated bone loss. *J Neurol Sci* 319:8-14
10. Dovoio A, Perazzolo L, Osella G, Ventura M, Termine A, Milano E, Bertolotto A, Angeli A (2004) Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. *J Clin Endocrinol Metab* 89:4923-4928

11. Bazelier MT, Staa T-Pv, Uitdehaag BMJ, Cooper C, Leufkens HGM, Vestergaard P, Herings RMC, Vries Fd (2012) Risk of fractures in patients with multiple sclerosis A population-based cohort study. *Neurology* 78:1967-1973
12. Bazelier MT, Staa Tv, Uitdehaag BM, Cooper C, Leufkens HG, Vestergaard P, Bentzen J, Vries Fd (2011) The risk of fracture in patients with multiple sclerosis: The UK general practice research. *Journal of Bone and Mineral Research* 26:2271-2279
13. Moen S, Celius E, Sandvik L, Nordsetten L, Eriksen E, Holmøy T (2011) Low bone mass in newly diagnosed multiple sclerosis and clinically isolated syndrome. *Neurology* 77:151-157
14. Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ, Price AL, Neale BM, Schizophrenia Working Group of the Psychiatric Genomics C (2015) LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nature Genetics* 47:291-295
15. Smith G, Ebrahim S (2003) 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? . *Int J Epidemiol* 32:1-22
16. Evans D, Smith G (2015) Mendelian Randomization: New Applications in the Coming Age of Hypothesis-Free Causality. *Annual Review of Genomics and Human Genetics* 16:327-350
17. Zheng J, Erzurumluoglu AM, Elsworth BL, et al. (2017) LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinformatics* 33:272-279
18. Altshuler DM, Gibbs RA, Peltonen L, et al. (2010) Integrating common and rare genetic variation in diverse human populations. *Nature* 467:52-58
19. International Multiple Sclerosis Genetics Consortium (2019) Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. *Science* 365:20.
20. IEU GWAS information: Fractured/broken bones in last 5 years. https://gwas.mrcieu.ac.uk/files/ukb-b-13346/ukb-b-13346_report.html
21. Li G, Thabane L, Papaioannou A, Ioannidis G, Levine M, Adachi J (2017) An overview of osteoporosis and frailty in the elderly. *BMC Musculoskelet Disord* 18:017-1403
22. Kemp J, Morris J, Medina-Gomez C, et al. (2017) Identification of 153 new loci associated with heel bone mineral density and functional involvement of GPC6 in osteoporosis. *Nat Genet* 49:1468-1475
23. Taekema DG, Gussekloo J, Maier AB, Westendorp RGJ, Craen AJMd (2010) Handgrip strength as a predictor of functional, psychological and social health. A prospective population-based study among the oldest old. *Age and Ageing* 39:331-337
24. Hanwell H, Banwell B (2011) Assessment of evidence for a protective role of vitamin D in multiple sclerosis. *Biochim Biophys Acta* 1812:202-212
25. Panel on Prevention of Falls in Older Persons AGSaBGS (2011) Summary of the Updated American Geriatrics Society/British Geriatrics Society clinical practice guideline for prevention of falls in older persons. *J Am Geriatr Soc* 59:148-157
26. Burgess S, Thompson S (2015) Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. *Am J Epidemiol* 181:251-260
27. Evans D, Davey SG (2015) Mendelian Randomization: New Applications in the Coming Age of Hypothesis-Free Causality. *Annu Rev Genomics Hum Genet* 16:327-350
28. Greco M F, Minelli C, Sheehan N, Thompson J (2015) Detecting pleiotropy in

- Mendelian randomisation studies with summary data and a continuous outcome. *Stat Med* 34:2926-2940
29. Davey Smith G, Hemani G (2014) Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet* 23:4
 30. Verbanck M, Chen C-Y, Neale B, Do R (2018) Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nature Genetics* 50:693-698
 31. Burgess S, Thompson S (2017) Interpreting findings from Mendelian randomization using the MR-Egger method. *Eur J Epidemiol* 32:377-389
 32. TwoSampleMR 0.5.6: Mendelian randomization with GWAS summary data. <https://mrcieu.github.io/TwoSampleMR/>
 33. MendelianRandomization: Mendelian Randomization Package. <https://cran.r-project.org/web/packages/MendelianRandomization/index.html>
 34. rondolab/MR-PRESSO. <https://github.com/rondolab/MR-PRESSO> 2022
 35. Hemani G, Zheng J, Elsworth B, et al. (2018) The MR-Base platform supports systematic causal inference across the human phenome. *eLife* 7:e34408
 36. Hemani G, Zheng J, Wade KH, et al. (2018) The MR-Base platform supports systematic causal inference across the human phenome. *eLife* 2018. doi: <https://doi.org/10.7554/eLife.34408>. *eLife*
 37. Raffield L, Louie T, Sofer T, et al. (2017) Genome-wide association study of iron traits and relation to diabetes in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL): potential genomic intersection of iron and glucose regulation? *Hum Mol Genet* 26:1966-1978
 38. (2022) GeneCards.
 39. Dharmarajan T, Avula S, Norkus E (2006) Anemia increases risk for falls in hospitalized older adults: an evaluation of falls in 362 hospitalized, ambulatory, long-term care, and community patients. *J Am Med Dir Assoc* 7:287-293
 40. Stephenson E, Nathoo N, Mahjoub Y, Dunn JF, Yong VW (2014) Iron in multiple sclerosis: roles in neurodegeneration and repair. *Nature Reviews Neurology* 10:459-468
 41. Bazelier M, van Staa T, Uitdehaag B, Cooper C, Leufkens H, Vestergaard P, Bentzen J, de Vries F (2011) The risk of fracture in patients with multiple sclerosis: the UK general practice research database. *J Bone Miner Res* 26:2271–2279
 42. Mazumder R, Murchison C, Bourdette D, Cameron M (2014) Falls in people with multiple sclerosis compared with falls in healthy controls. *PLoS One* 9:
 43. Trajanoska K, Seppala LJ, Medina-Gomez C, et al. (2020) Genetic basis of falling risk susceptibility in the UK Biobank Study. *Communications Biology* 3:

Table 1. Genetic correlations between MS and musculoskeletal phenotypes and heritability by LD score regression

Trait	rG	SE_rG	Z_rG	P_rG	h2_obs	h2_obs_se	h2_int	h2_int_se
Fractured/broken bones in last 5 years	-0.017	0.047	-0.371	0.711	0.019	0.002	1.007	0.008
Falls in the last year	0.105	0.041	2.591	0.010	0.033	0.002	1.004	0.008
Frailty	0.151	0.087	1.741	0.082	0.062	0.028	1.056	0.009
Heel bone mineral density (BMD)	-0.003	0.025	-0.132	0.895	0.297	0.033	1.080	0.035
Whole body fat-free mass	0.035	0.025	1.395	0.163	0.291	0.012	1.114	0.029
Hand grip strength (right)	-0.066	0.027	-2.454	0.014	0.104	0.004	1.058	0.013
Hand grip strength (left)	-0.067	0.028	-2.427	0.015	0.104	0.004	1.055	0.012
Leg fat-free mass (right)	0.060	0.025	2.359	0.018	0.266	0.011	1.099	0.026
Leg fat-free mass (left)	0.062	0.025	2.435	0.015	0.268	0.011	1.092	0.025
Arm fat-free mass (right)	0.019	0.025	0.766	0.444	0.267	0.011	1.091	0.026
Arm fat-free mass (left)	0.030	0.025	1.191	0.234	0.267	0.011	1.097	0.025

rG: genetic correlation between two traits, SE_rG: standard error of the genetic correlation, Z_rG: Z score of the genetic correlation, P_rG: p value of the genetic correlation. h2_int: heritability intercept

Table 2. Univariable MR effects between exposure (MS) and outcomes (musculoskeletal outcomes and risk factors)

Exposure	Outcomes	MR effects between MS and outcomes							
		MR method	#SNP	beta	se	<i>p value</i>	Q value	OR	95% CI
Multiple Sclerosis	Musculoskeletal traits								
	Fracture	IVW	109	0.002	0.001	0.001		1.002	1.000-1.004
		MR-PRESSO*		0.002	0.001	0.007	0.056	1.002	1.001-1.003
	Fall	IVW	109	0.004	0.001	0.005		1.004	1.002-1.006
		MR-PRESSO		0.004	0.001	0.002	0.018	1.004	1.001-1.006
	Frailty (continuous)	IVW	152	0.012	0.004	0.007		-	0.004-0.020
		MR-PRESSO		0.009	0.004	0.021	0.147	-	0.001-0.017
	Musculoskeletal risk factors								
	Heel BMD	IVW	110	-0.002	0.005	0.722	0.722	-	-
	Whole body fat free mass	IVW	109	0.004	0.004	0.258	0.722	-	-
	Appendicular fat free mass	IVW	110	0.006	0.007	0.402	0.722	-	-
	Grip strength(right)	IVW	109	-0.004	0.003	0.183	0.722	-	-
	Grip strength(left)	IVW	109	-0.002	0.003	0.389	0.722	-	-
Vitamin D	IVW	105	-0.003	0.003	0.427	0.722	-	-	

Abbreviation: IVW, inverse variance weighted; MR-PRESSO, Mendelian Randomization Pleiotropy RESidual Sum and Outlier

No horizontal pleiotropy was found in all analysis tested by Egger regression intercept test.

Heterogeneity test (Q test) was significant in all analysis except MS->fracture MR analysis.

To overcome the heterogeneity of SNPs effects, MR-PRESSO outlier tests were applied and outlier corrected results were presented along with results from IVW method.

*No outlier detected

Table 3. Multivariable MR between MS and fall adjusting for musculoskeletal risk factor

	MR effects between MS and fall				
	beta	se	pval	OR	95% CI
Unadjusted model	0.004	0.001	0.005	1.004	1.002-1.006
Adjusted by frailty	0.002	0.001	0.058	1.002	1.000-1.004
Adjusted by appendicular fat free mass	0.004	0.001	0.004	1.004	1.002-1.006
Adjusted by whole body fat free mass	0.004	0.001	0.004	1.004	1.002-1.006
Adjusted by heel BMD	0.004	0.001	0.004	1.004	1.002-1.006
Adjusted by right grip strength	0.003	0.001	0.011	1.003	1.000-1.005
Adjusted by left grip strength	0.003	0.001	0.008	1.003	1.000-1.005
Adjusted by all except frailty	0.003	0.001	0.022	1.003	1.000-1.005
Adjusted by all	0.002	0.001	0.184	1.002	1.000-1.004

Fig 1. Conceptual model of univariable and multivariable Mendelian Randomization

